129 related articles for article (PubMed ID: 8608504)
1. Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma.
Schleusener JT; Tazelaar HD; Jung SH; Cha SS; Cera PJ; Myers JL; Creagan ET; Goldberg RM; Marschke RF
Cancer; 1996 Apr; 77(7):1284-91. PubMed ID: 8608504
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer.
Gregorc V; Spreafico A; Floriani I; Colombo B; Ludovini V; Pistola L; Bellezza G; Viganò MG; Villa E; Corti A
Cancer; 2007 Aug; 110(4):845-53. PubMed ID: 17599769
[TBL] [Abstract][Full Text] [Related]
3. The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study.
Bonner JA; McGinnis WL; Stella PJ; Marschke RF; Sloan JA; Shaw EG; Mailliard JA; Creagan ET; Ahuja RK; Johnson PA
Cancer; 1998 Mar; 82(6):1037-48. PubMed ID: 9506347
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy.
Howe MC; Chapman A; Kerr K; Dougal M; Anderson H; Hasleton PS
Histopathology; 2005 Feb; 46(2):195-201. PubMed ID: 15693892
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine differentiation as an indicator of chemosensitivity and prognosis in nonsmall cell lung cancer.
Petrović M; Baskić D; Banković D; Ilić N
Biomarkers; 2011 Jun; 16(4):311-20. PubMed ID: 21595568
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
[TBL] [Abstract][Full Text] [Related]
7. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.
Kawai O; Ishii G; Kubota K; Murata Y; Naito Y; Mizuno T; Aokage K; Saijo N; Nishiwaki Y; Gemma A; Kudoh S; Ochiai A
Cancer; 2008 Sep; 113(6):1387-95. PubMed ID: 18671239
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group.
Figlin RA; Crowley JJ; Jacobs EL; Muirhead M; Goodwin JW; Rinehart JJ; Livingston RB
Cancer; 1996 Sep; 78(5):998-1003. PubMed ID: 8780537
[TBL] [Abstract][Full Text] [Related]
9. Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy.
Yamazaki S; Sekine I; Matsuno Y; Takei H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T; Kodama T; Asamura H; Tsuchiya R; Saijo N
Lung Cancer; 2005 Aug; 49(2):217-23. PubMed ID: 16022916
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
[TBL] [Abstract][Full Text] [Related]
11. Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing.
Shaw GL; Gazdar AF; Phelps R; Linnoila RI; Ihde DC; Johnson BE; Oie HK; Pass HI; Steinberg SM; Ghosh BC
Cancer Res; 1993 Nov; 53(21):5181-7. PubMed ID: 8221655
[TBL] [Abstract][Full Text] [Related]
12. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study.
Franciosi V; Cocconi G; Michiara M; Di Costanzo F; Fosser V; Tonato M; Carlini P; Boni C; Di Sarra S
Cancer; 1999 Apr; 85(7):1599-605. PubMed ID: 10193952
[TBL] [Abstract][Full Text] [Related]
13. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic factors affecting survival and response in patients with advanced non-small cell lung cancer treated with combination chemotherapy].
Takifuji N; Fukuoka M; Negoro S; Takada M; Kusunoki Y; Matsui K; Masuda N; Ryu S; Sakai N; Kubota K
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):429-34. PubMed ID: 2157364
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma.
Arinaga M; Noguchi T; Takeno S; Chujo M; Miura T; Uchida Y
Cancer; 2003 Jan; 97(2):457-64. PubMed ID: 12518370
[TBL] [Abstract][Full Text] [Related]
16. Nonsmall cell lung carcinoma with neuroendocrine differentiation--an entity of no clinical or prognostic significance.
Ionescu DN; Treaba D; Gilks CB; Leung S; Renouf D; Laskin J; Wood-Baker R; Gown AM
Am J Surg Pathol; 2007 Jan; 31(1):26-32. PubMed ID: 17197916
[TBL] [Abstract][Full Text] [Related]
17. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587).
Chang AY; Kim K; Boucher H; Bonomi P; Stewart JA; Karp DD; Blum RH
Cancer; 1998 Jan; 82(2):292-300. PubMed ID: 9445185
[TBL] [Abstract][Full Text] [Related]
19. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of glutathione S-transferase-Pi can predict chemotherapy response in patients with nonsmall cell lung carcinoma.
Bai F; Nakanishi Y; Kawasaki M; Takayama K; Yatsunami J; Pei XH; Tsuruta N; Wakamatsu K; Hara N
Cancer; 1996 Aug; 78(3):416-21. PubMed ID: 8697385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]